Key result
Citrate plasma yields ~4.5-fold higher PF4 levels than CTAD, altering UFH anti-Xa measurements.
Why the study?
Inter-assay variability in anti-Xa levels during UFH management can be influenced by dextran sulfate presence and PF4 plasma levels, but their associations in different clinical settings remain unclear.
Do PF4 plasma levels and the presence of dextran sulfate in anti-Xa reagents affect UFH anti-Xa levels in critically ill patients?
Observational (n=144)
Yes
Do PF4 plasma levels and the presence of dextran sulfate in anti-Xa reagents affect UFH anti-Xa levels in critically ill patients?
Anti-Xa assays for UFH monitoring show significant variability depending on the presence of dextran sulfate in reagents and PF4 levels, highlighting the need for better assay standardization.
Answers are grounded in this paper and cite their sources.
Variability in anti-Xa levels from PF4 and DXS warrants assay caution in critically ill UFH patients; supports standardization research but should not yet alter practice.
Chromogenic anti-Xa assay is currently used in the management of patients on unfractionated heparin (UFH). It has been shown that inter-assay variability in anti-Xa levels can be explained in part by the presence or absence of dextran sulfate (DXS) in the reagents. DXS has the ability to dissociate UFH from neutralizing proteins, including platelet factor 4 (PF4). Investigate whether PF4 plasma levels along with the presence/absence of DXS in anti-Xa reagents are associated with variations in UFH anti-Xa levels in different clinical situations. In the prospective multicenter study DEXHEP-NCT04700670, critically ill patients on UFH therapy (four groups) were recruited. Blood was collected into citrate and CTAD tubes. Chromogenic anti-Xa levels were assessed using seven reagent/analyzer combinations including two without DXS. Plasma PF4 was measured by ELISA (Zymutest-PF4-Hyphen-Biomed). A total of 144 patients were analyzed: average PF4 levels in citrate plasma samples were consistently higher than in CTAD ones (206 vs. 46 ng/mL, p < 10−4), regardless of the patient group. Using a linear mixed-effect model, we found a significant effect of both DXS and PF4 on anti-Xa level, with a significant interaction term (p < 10−4). Considering the 0.3 to 0.7 IU/mL therapeutic range, agreement between anti-Xa values (Liquid-anti-Xa/DXS-free vs. Biophen-LRT/DXS) was observed in roughly two-thirds of the patients. PF4 levels slightly affects anti-Xa levels, the use of CTAD tubes minimizing the effect. However, PF4 levels do not fully explain the differences of anti-Xa levels observed in the presence or absence of DXS, which has a greater effect. Anti-Xa assays require better standardization.
No takes yet. Share an insight, caveat, or question.
Savard et al. (2025) conducted an observational in Critically ill patients on unfractionated heparin (UFH) therapy (n=144). Citrate tubes vs. CTAD tubes was evaluated on PF4 plasma levels (ng/mL) (p=< 10−4). In critically ill patients on UFH, average PF4 levels were higher in citrate versus CTAD plasma samples, and both DXS and PF4 affected anti-Xa levels.
Synapse has enriched 10 related papers. Consider them for comparative context: